Indaptus Therapeutics Inc (INDP) - News Archive

Indaptus Therapeutics Strengthens Its Footing: A Strategic Move Amid Advancements in Cancer TreatmentNew York, January 13, 2025 Indaptus Therapeutics, Inc. (Nasdaq: INDP), a forward-thinking biotechnology firm entrenche...

Indaptus Therapeutics Inc. a leader in immunotherapy innovation, has made significant strides with its cutting-edge Decoy platform, which focuses on combating cancer through novel immunotherapeutic approaches. Recently,...

Exploring New Frontiers: Indaptus Therapeutics Unveils Promising Phase 1 Trial Results for Decoy20 and Validates Pulse-Prime Hypothesis at SITC 2024 Indaptus Therapeutics, a pioneering force in the field of immunotherap...

:Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company renowned for developing groundbreaking treatments for cancer and viral infections, recently disclosed promising new safety data pertain...

Indaptus Therapeutics, Inc. Secures $3.0 Million in Funding for Groundbreaking Cancer and Viral Infection TreatmentsAugust 7, 2024 - Indaptus Therapeutics, Inc. (Nasdaq: INDP), a pioneering clinical stage biotechnology...

IntroductionIndaptus Therapeutics Inc, a leading biopharmaceutical company in the healthcare sector, is set to present the initial clinical data on their lead product candidate, Decoy20, at the upcoming STING & TLR-Targ...

Indaptus Therapeutics, a leading biopharmaceutical company, has recently unveiled positive data from the ongoing Phase 1 trial of their ground-breaking drug, Decoy20. This breakthrough approach, known as the pulse-prime...

Indaptus Therapeutics Unveils Promising Phase 1 Clinical Trial Data of Decoy20 at ASCO Annual MeetingIndaptus Therapeutics, a pioneering biotechnology company focused on the development of innovative therapies for cance...

Significant Advancement in Immuno-Oncology: Indaptus Therapeutics Completes First Multiple-Dose Administration of Decoy20 in Phase 1 Trial On May 22, 2024, Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage bi...

Boosting the Immune System s Ability to Fight Tumors: The Potential of the Decoy PlatformRecent studies have shed light on a promising approach to enhancing the immune system s ability to fight tumors. Indaptus Therapeu...

Indaptus Therapeutics, a leading biopharmaceutical company, has revealed encouraging results from the completion of the second cohort in their Phase 1 clinical trial for the investigational drug, Decoy 20. The positive...